Skip to main content

Dexpramipexole Fails in ALS


Biogen Idec reports that topline results of a phase 3 trial investigating dexpramipexole in patients with amyotrophic lateral sclerosis (ALS) failed to show a benefit on primary or secondary outcomes.
The trial, called EMPOWER and including 943 patients with ALS, failed to meet the primary outcome, a joint rank analysis of function and survival called the Combined Assessment of Function and Survival. Other endpoints, including functional decline, survival, or respiratory decline, and subgroup analyses also failed to show efficacy with treatment, overall or for any subpopulation.
"Based on these results, Biogen Idec will discontinue development of dexpramipexole in ALS," a statement from the company said.
"We share the disappointment of members of the ALS community, who had hoped that dexpramipexole would offer a meaningful treatment option," Douglas E. Williams, PhD, executive vice president of research and development at Biogen Idec, said in the company statement.
"I am deeply saddened by this news and know how disappointing it is for the thousands of people living with ALS and their families," said Jane H. Gilbert, president and CEO of The ALS Association in a statement. "On behalf of The ALS Association, I want to assure the ALS community that we are doing everything we can to work with companies to advance treatments and bring them to patients as soon as possible."
Dexpramipexole had been given a fast-track designation from the US Food and Drug Administration (FDA). It has also been granted orphan drug status by both the FDA and the European Medicines Agency.
In their statement, the company reassures the community that they remain committed to research in the ALS space. Efforts include the recent establishment of a research collaboration with Duke University and HudsonAlpha Institute to sequence the genome of up to 1000 people with ALS over the next 5 years, collaboration in a research consortium with several leading research centers to identify new treatments, as well as "significant funds" committed to the University of Massachusetts Medical School ALS Champion fund to increase awareness and support basic and clinical science research into ALS and other neurodegenerative diseases.
"As a physician who has treated people with ALS, I hoped with all my heart for a different outcome," said Douglas Kerr, MD, PhD, director of neurodegeneration clinical research at Biogen Idec. "While these results were not what we expected, we hope these data will provide a foundation for future ALS research."
Riluzole ( Rilutek, sanofi-aventis) has shown modest benefits in a measure of survival time and is currently the only approved treatment for ALS.

Comments

  1. Varicose Veins Phoenix15 May 2013 at 05:16

    This is a vein and vascular center that has multiple locations. They are located in near PHOENIX, ARIZONA, USA. Office locations are, Surprise, Arizona, USA, - Goodyear, Arizona USA, Chandler, Arizona USA and Gilbert , Arizona USA. These cities surround Phoenix, so we want to focus on each city and about a 20 mile radius around each one as well as Phoenix itself since it is in the center of all these cities.

    ReplyDelete

Post a Comment

Popular posts from this blog

Contact Precautions May Have Unintended Consequences

Contact precautions, including gloves, gowns, and isolated rooms, have helped stem the transmission of hospital pathogens but have also had some negative consequences, according to findings from a new study. Healthcare worker (HCWs) visited patients on contact precautions less frequently than other patients and spent less time with those patients when they did visit, report Daniel J. Morgan, MD, from the University of Maryland School of Medicine and the Veterans Affairs (VA) Maryland Health Care System, Baltimore, and colleagues. Moreover, patients on contact precautions also received fewer outside visitors. "Less contact with HCWs suggests that other unintended consequences of contact precautions still exist," Dr. Morgan and coauthors write. "The resulting decrease in HCW contact may lead to increased adverse events and a lower quality of patient care due to less consistent patient monitoring and poorer adherence to standard adverse event prevention methods (such...
Post a Comment
Read more

FDA Decision Delayed for Truvada in HIV PrEP

June 11, 2012 — The US Food and Drug Administration (FDA) has delayed its decision on allowing the use of tenofovir disoproxil fumarate/emtricitabine ( Truvada , Gilead) as preexposure prophylaxis (PrEP) so that the proposed risk evaluation and mitigation strategy (REMS) can be reviewed. In early May, the FDA's Antiviral Drugs Advisory Committee  strongly backed  approval of the first-ever drug for the prevention of sexually acquired HIV-1 infection. However, concerns by the panel at the time included that people may neglect condom use if they feel they are protected by PrEP. Panelists were also concerned that uninfected people taking PrEP who become infected with HIV may not switch to a 3-drug regimen as recommended. According to the company, the FDA has postponed the target date to September 14 so it can review Gilead's REMS plan to help ensure that patients will not misuse the drug. The committee's recommendation for supplemental approval of tenofovir/emtricit...
Post a Comment
Read more

Antidepressants Linked to Higher Diabetes Risk in Kids

Pediatric patients who use antidepressants may have an elevated risk for type 2 diabetes, the authors of a new study report. In a retrospective cohort study of more than 119,000 youths 5 to 20 years of age, the risk for incident type 2 diabetes was nearly twice as high among current users of certain types of antidepressants as among former users, Mehmet Burcu, PhD, and colleagues report in an article  published online October 16 in  JAMA Pediatrics . The risk intensified with increasing duration of use, greater cumulative doses, and higher daily doses of these antidepressants. The findings point to a growing need for closer monitoring of these products, including greater balancing of risks and benefits, in the pediatric population, the authors caution. They undertook the study because, despite growing evidence of an association between antidepressant use and an increased risk for type 2 diabetes in adults, similar research in pediatric patients was scarce. "To our know...
Post a Comment
Read more